Research Progress on the Relationship between Voriconazole Genetic Polymorphisms and Blood Drug Concentrations
Voriconazole(VRZ)is a broad-spectrum antifungal drug widely used to treat aggressive fungal infections.However,there are significant individual differences in the pharmacokinetic characteristics of VRZ,including nonlinear pharmacokinetics and high adverse reaction rates.Gene polymorphisms,especially those related to CYP enzyme,have significant effects on the metabolic rate and blood con-centration of VRZ.During VRZ treatment,it is important to adjust the drug dose according to the individual genotype and blood concen-tration.In this study,the narrow therapeutic window and high incidence of adverse reactions of VRZ were discussed,emphasizing the key role of gene polymorphism in the pharmacokinetics and pharmacodynamics of VRZ.In particular,the effects of polymorphisms of CYP family genes(such as CYP2C19,CYP2C9,CYP3A),POR genes,FMO3 genes,and transporter genes(such as SLCO2B1,ABCB1)on VRZ blood concentration and individual therapy strategies were analyzed.The aim is to provide scientific basis for the individualized treat-ment of VRZ by summarizing the current research results,reduce the adverse reactions,improve the therapeutic effect,and point out the direction for future research.
VoriconazoleGenetic polymorphismsBlood drug concentrationsIndividualized therapyCurative effectAdverse reaction